07/12/2022

Provepharm receives FDA approval for BLUDIGO™ (indigotindisulfonate sodium, USP) Injection

Marseille, France and Collegeville, PA, USA - July 12, 2022 - Provepharm, a French company specialized in the development of pharmaceutical applications, today announces that it has received FDA New Drug Approval for the marketing of BLUDIGO™, its indigo carmine injectable (Indigotindisulfonate Sodium) drug product. BLUDIGO is a diagnostic dye indicated for use as a visualization aid in the cystoscopic assessment of the integrity of the ureters in adults, following urological and gynecological open, robotic or endoscopic surgical procedures.

“BLUDIGO is the second Provepharm product to obtain marketing authorization from the FDA,” said Frederick Girard, chief medical officer at Provepharm. “This new success validates our strategy, based on a high level of investment in R&D, aimed at improving, on a daily basis, patients’ lives and healthcare professionals’ work.”

“We are very proud of this achievement,” said Michel Féraud, president and founder of the Provepharm group. “In 2016, we were the first to register a methylene blue injection product in the US and I am happy that our newly approved BLUDIGO drug product will also soon be available to US patients.”

This additional approval is a clear validation of the group’s worldwide strategy, implemented through its operations in both Europe and the United States. It aims to develop new medicines and diagnostic products from known molecules, to respond to unmet medical needs and to reset drugs in different indications, in this case, the intraoperative assessment of the ureter’s integrity.

Press release >

05/ 25/2022

Act to improve life.

Act is the commitment tomobilize our resources to achieve our mission.

Act is daring to refuse the status quo and to define new standards of innovation.

Act with integrity is having a positive, significant and lasting impact on our ecosystem

Provepharm - L'Essentiel - 2021 - At a Glance

05/11/2022

Provepharm will participate in the HOPIPHARM Francophone Congress of Hospital Pharmacy, which will take place from 18 to 20 May 2022 at the Lille Congress Center.

This congress, organized by the SYNPREFH*, is the unmissable event of the hospital pharmacy, combining high-level training and work sessions and numerous exchanges between all the delegates.

On this occasion, our sales, marketing and medical teams will be present via a stand to promote our entire portfolio and respond to the questions and needs of healthcare professionals. We will also propose to delegates to participate in the Provepharm Interactive Corner organized on Wednesday, May 18 from 12:30 to 13:00 to develop knowledge on endoscopic and surgical dyes available on the market. This session entitled: "Which dye for what use? The answer in 10 questions" will be led by Dr. Chasseigne (Pharmacist Hospital Practitioner - CHU Carémeau Nîmes) on the basis of a quiz addressing the status, indications, ways and methods of administration. This development will be complemented by the presentation of the results and lessons learned from the audit of practices carried out within its health institution. A session dedicated to the exchange and sharing of knowledge!

* The SYNPREFH is the national union that brings together pharmacists in single-owned and university hospitals, assistants and attachés who work in all types of hospitals.

03/14/2022

Provepharm will be closer to healthcare professionals at the JFHOD congress from March 17 to 20, 2022 at the Palais des Congrès in Paris, and at the EAHP congress from March 23 to 25, 2022 in Vienna, Austria.

March 2022 is a busy month for Provepharm's sales and marketing team, which will be present at 2 major congresses. Provepharm will participate for the first time in the JFHOD congress (French Days of Hepato-gastroenterology and Digestive Oncology), which will take place at the Palais des Congrès in Paris from March 17 to 20, 2022. This congress, organized by the SNFGE, French National Society of Gastro-Enterology, in collaboration with the FMC-HGE, French National Association for Continuing Education in Hepato-Gastro-Enterology, is the reference congress for diseases and cancers of the digestive. Each year, it brings together several thousand participants from French-speaking countries: hepato-gastroenterologists, oncologists, digestive surgeons, pediatric gastroenterologists, etc. The 2022 theme for the JFHOD is Hepato-Gastro-Enterology 2.0 (impact of Big Data, Artificial Intelligence, rise of e-health, etc.). Provepharm will be present and visible during the 4 days of the congress thanks to a 12m2 stand which will allow participants to discuss their clinical practice with the delegates. To know more (in French only).

Provepharm will also participate for the first time in the annual congress of the European Association of Hospital Pharmacists (EAHP) which will take place in Vienna, Austria, from March 23 to 25, 2022. This European association represents 23,000 hospital pharmacists in 35 countries. The 26th edition of the congress is also the 50th anniversary of the association and will bring together nearly 4,000 Hospital Pharmacists from Europe and around the world. The main theme this year is "Changing roles in a changing world": the congress will deal with therapeutic innovations, improved care and the role of the hospital pharmacist. Provepharm will be present and visible during the 3 days of the congress thanks to an 8m2 stand which will allow to exchange with the delegates and to understand the practices in the different countries. 3 hospital pharmacists were invited to the congress by Provepharm in order to participate in the continuous improvement of practices in the hospital environment. To know more.

02/28/2022

The form changes but not the substance...

We are proud to announce the launch of the new company logo in line with our perpetuous evolution. Without drawing a line on the past and partially using our visual identity, this new graphic design brings together innovation, commitment and modernity, in line with our growth. Our company has grown and evolved over the past 20 years, and we felt it was time to reaffirm our identity. As we were able to do so well with our historic product, the methylene blue, then with our new developments, we finally tackled the revitalization of our logo. Reflecting who we are, it will follow us in our development and our mission to improve life.

After careful consideration, we have chosen a new logo that affirms our positioning: to improve the lives of patients, employees and our eco-system. The color blue is associated with the medical and pharmaceutical fields but also with our DNA, the methylene blue. The semicircle is the proof that we want to move forward, this movement from left to right represents our philosophy. Provepharm recovers a molecule to release its full potential to improve life: this is our mission.

Our objective over the next months will be to harmonize our graphic identity and to update our documentation, our packaging, but also our digital tools... More than a simple change of logo, changing our visual identity is a truly impactful project, which needs to be conducted with rigor and following specific steps. We look forward to taking full advantage of this new identity! We hope you like it as much as we do.

Rather than writing too much, we invite you to watch this short film:

11/25/2021

Following GMP certification earned in 2019 for its new production unit, Provepharm now has full control over its production chain for Europe and the US.

Marseille, France, November 25, 2021 - Provepharm Life Solutions, a French private pharmaceutical company that finds new applications for well-known molecules, today announces that it has been granted FDA (Food and Drug Administration) authorization to produce its own Active Pharmaceutical Ingredients (APIs) in order to manufacture drugs for the US market.

Shortly after opening its production plant in 2019, following an inspection by the French National Agency for the Safety of Medicines and Health Products (ANSM), Provepharm was awarded GMP (Good Manufacturing Practice) certification to produce its own active ingredients for European countries. The plant is located at the Château-Gombert technopole in Marseille, France.

In line with its Horizon 2025 strategic plan, Provepharm has also now obtained authorization from the US authorities. This is further evidence of the safety, compliance and excellence of production at Provepharm and will enable the company to produce its first clinical batches more rapidly.

“This FDA authorization allows us to advance a key part of our strategy, which is to increase our independence by taking control of our production. The COVID-19 pandemic has shown how crucial this is, not only for French industry, but on a global scale. By controlling all parts of our supply chain we can now take on our full responsibility as a pharmaceutical company. We are delighted to welcome Damien Holly to support this new stage in our development, which will be crucial to our growth,” said Michel Feraud, CEO of Provepharm Life Solutions.

In summer 2021, Provepharm appointed Damien Holly as Chief Operations and Quality Officer to support the company’s international industrial development. Holly, an Irish chemist, specializes in supply chain management and has run the day-to-day operations at over 40 facilities for companies such as Novartis, Pfizer and Eli Lilly.

“It’s a real honor for me to join Provepharm. I completely subscribe to the project that has been presented to me and I’m certain that my expertise in technical and operational production roles, together with my international experience, puts me in a position to help the group achieve its ambitions for growth,” said Damien Holly.

Provepharm now has the capacity to develop and validate its APIs synthesis. The approved process can then be transferred under license to its industrial partners. The production plant has been operating around the clock for over a year, with highly qualified staff working at the production plant facility to meet increasing client demands.

Provepharm is continuing to internally develop its product portfolio and is planning a further external growth project in the near future, as it progresses forward on its roadmap.

Press release >

October 7, 2021

Temporary Importation of Cefotaxime for Injection to Address Drug Shortage:

10/2021

Kas, Turkey, October 9, 2021 - This Saturday, October 9, Arnaud Jerald won the world title in Kas, Turkish waters, during the Open Water Freediving World Championships. The young freediver is wearing the colors of Provepharm Life Solutions.

He took the start of the competition quite serene this morning since his main opponent, the Russian Alexey Molchanov, was disqualified yesterday during a no-fins dive thus prohibiting him from diving today. As a result, during last night's announcements, he relied on a "safe" depth of 116 m, which he has done several times in training, taking into account the increasingly stressful conditions in competition, as well as the water conditions of the day.

At 9:20 a.m. local time, he descended to a depth of 116 meters with the help of his fins, 2 meters less than the absolute world record for the discipline.

After 1 minute and 34 seconds, Arnaud reached the depth of -116m, followed by an underwater drone that was broadcasting the competition live. He came back up with a perfect swimming technique, then realized his surface protocol in 5 seconds, in front of the judges who gave him the white card, synonymous with a validated dive. The freedive lasted 3 minutes and 18 seconds in total.

Already author of 4 world records in the discipline, including 2 records last July in the Bahamas during the prestigious Vertical Blue (-116 m and -117 m), this is the first world champion title for Arnaud Jerald, who continues to impress by his extraordinary progression and his regularity at this level of competition. This performance in bi-palms took place on the last day of the world championships.

During this 2021 season Arnaud covered 12,507 m (or more than 12 km) in apnea, wearing his fins, which represents 93 dives in total.

Read more >

09/08/2021

New round of funding enables pharma company to make major steps forward in its Horizon 2025 strategy.

Marseille, France, September 8, 2021 - Provepharm Life Solutions, a private French pharmaceutical company that finds new applications for well-known molecules, today announces a €120 million ($142.3M) strategic funding. Tikehau Capital will provide the funds and joins the group’s pool of banking investors, including Société Générale, BNP Paribas, Banque Populaire Méditerranée, Crédit Agricole Alpes Provence and Bpifrance. This new investment will enable the group to speed up its internal R&D and external growth projects, in line with its Horizon 2025 strategy.

The 2020 financial year saw outstanding results and strong growth for Provepharm Life Solutions - in spite of the ongoing global pandemic. This includes a 30% increase in turnover and, following its acquisition of Apollo Pharmaceuticals in December 2020, the successful integration of a portfolio of products. The company expects to use the new funds to plan significant structural operations in the years to come.

“Tikehau Capital is delighted to support the Provepharm pharmaceutical group with its highly innovative projects and its ambition for international growth. We are grateful to Michel Feraud and his team for trusting us. As well as providing a private debt financing solution, Tikehau Capital will become a long-term partner of Provepharm, allowing it to capitalize on promising opportunities in high-growth markets,” said Cécile Mayer-Lévi, head of private debt activity at Tikehau Capital.

Provepharm’s goal as a pharmaceutical laboratory is to create innovative ways to maximize the potential of all molecules, in order to offer treatments that will improve the lives of patients. Strengthening its financial resources with this major and favorable deal will enable the group to retain its independence in terms of capital.

“Our consistent performance, paired with our ambitious long-term plans, continues to strengthen our partnership with our financial partners. This new investment means that we can accelerate the time-frame for our Horizon 2025 strategic plan and actively contribute to advances in treatment that are sure to benefit patients,” explained Michel Feraud, CEO of Provepharm Life Solutions.

Over the coming months, the company plans to consolidate its position as an international and independent pharmaceutical laboratory, specifically by hiring new staff in France and the United States, and increasing the size of its laboratories in Marseille, so that it can continue to manage its entire value chain.

Advisers on company side:

Finance: Bucéphale Finance (David Orban)
Legal: BBLM (Myriam Cuvellier) - De Pardieu Brocas Maffei (Jean-François Pourdieu)

Advisers on financial side:

Bank legal: Simmons & Simmons (Colin Millar, Iva Parvanova)
Tikehau Capital legal: Hogan Lovells (Alexander Premont, Stéphane Huten, Lorène Sani)

Press release >

09/2021

Provepharm will participate in the 16th "Convergences Santé Hôpital" meeting, which will take place from September 14th to 17th 2021 at the Alpexpo Congress Center in Grenoble.

This congress, organized by the SNPHPU*, is one of the main forums for exchanges between hospital pharmacists and French health care professionals, highlighting new perspectives and therapeutic innovations for health care professionals and patients.

For the first time, Provepharm Life Solutions will organize a symposium "Pharmaceutical aspects of dyes and their use in clinical practice" where a cross-lighting of the pharmacist Dr. Carole PAILLET (Head of Pharmacy Department, Hospices Civils de Lyon) and the clinician Pr. Jean-Christophe SAURIN (Head of the Hepato-Gastroenterology Department, Hospices Civils de Lyon) will discuss the use of surgical and endoscopic dyes, from their manufacture and referencing in health care institutions to their use in routine clinical practice. This session, moderated by Dr Valérie MINETTI (Hospital Pharmacist, La Timone Hospital, Marseille), will also be an opportunity to discover Provepharm's know-how and its commitment to Hospital Pharmacists through the introduction of our Medical Director in charge of development, Dr Frederick Girard.

See you in Grenoble on Wednesday, September 15th at 2pm to attend this session, or on the Provepharm booth n° 22!

More information here (in French only).

*National Union of Hospital Pharmacists